Donepezil: An update

Expert Opinion on Pharmacotherapy

Volumn 8, Issue 7, 2007, Pages 1011-1023

  Seltzer, Ben ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Alzheimer's disease; Cholinergic system; Cholinesterase inhibitors; Dementia; Donepezil

Indexed keywords

ACETYLCHOLINESTERASE; ALPHA TOCOPHEROL; ANTIPARKINSON AGENT; APOLIPOPROTEIN E; APOLIPOPROTEIN E EPSILON4; CHOLINESTERASE INHIBITOR; DONEPEZIL; MEMANTINE; PLACEBO; RISPERIDONE; RIVASTIGMINE; SERTRALINE; UNCLASSIFIED DRUG; INDAN DERIVATIVE; NOOTROPIC AGENT; PIPERIDINE DERIVATIVE;

ALZHEIMER DISEASE; ARTICLE; ATTENTION DEFICIT DISORDER; AUTISM; BRAIN FUNCTION; CLINICAL TRIAL; COGNITIVE DEFECT; COST BENEFIT ANALYSIS; DAILY LIFE ACTIVITY; DIFFUSE LEWY BODY DISEASE; DISEASE SEVERITY; DOWN SYNDROME; DRUG ABSORPTION; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; ENZYME INHIBITION; FRONTOTEMPORAL DEMENTIA; GILLES DE LA TOURETTE SYNDROME; HUMAN; MULTIINFARCT DEMENTIA; MULTIPLE SCLEROSIS; PARKINSON DISEASE; PATHOGENESIS; SCHIZOPHRENIA; TRAUMATIC BRAIN INJURY; UNSPECIFIED SIDE EFFECT; METABOLISM; REVIEW;

ALZHEIMER DISEASE; CHOLINESTERASE INHIBITORS; CLINICAL TRIALS; HUMANS; INDANS; NOOTROPIC AGENTS; PARKINSON DISEASE; PIPERIDINES;

EID: 34249657887     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.8.7.1011     Document Type: Article

References (173)

1. IMS HEALTH: Weekly Prescription Audit. Fairfield, CT, USA.
2. IMBIMBO BP: Pharmacodynamic-tolerability relationships of cholinesterase inhibitors for Alzheimer's disease. CNS Drugs (2001) 15(5):375-390.
3. JANN MW, SHIRLEY KL, SMALL GW: Clinical pharmacokinetics and pharmacodynamics of cholinesterase inhibitors. Clin. Pharmacokinet. (2002) 41(10):719-739.
4. WILKINSON DG, FRANCIS PT, SCHWAM E, PAYNE-PARRISH J: Cholinesterase inhibitors used in the treatment of Alzheimer's disease: the relationship between pharmacological effects and clinical efficacy. Drugs Aging (2004) 21(7):453-478.
5. SELTZER B: Donepezil: a review. Expert Opin. Drug Metab. Toxicol. (2005) 1(3):527-536.
6. ROMAN GC, ROGERS SJ: Donepezil: a clinical review of current and emerging indications. Expert Opin. Pharmacother. (2004) 5(1):161-180.
7. SELTZER B: Donepezil in the treatment of dementia. Aging Health (2005) 1(1):7-17.
8. WIMO A, JONSSON L, WIN BLAD B: An estimate of the worldwide prevalence and direct costs of dementia in 2003. Dement. Geriatr. Cogn. Disord. (2006) 21(3):175-181.
9. WIMO A, WINBLAD B, AGUERO TORRES H, VON STRAUSS E: The magnitude of dementia occurrence in the world. Alzheimer Dis. Assoc. Disord. (2003) 17:63-67.
10. FERRI CP, PRINCE M, BRAYNE C et al.: Global prevalence of dementia: a Delphi consensus study. Lancet (2005) 366(9503):2112-2117.
11. DATAMONITOR: Treatment algorithm 2002. Alzheimer's disease: the physicians choice, March 2002.
12. MARKET MEASURES/COZINT: Treatment of Alzheimer's disease, Study IX. NOP World, May 2003.
13. ZHANG HY, TANG XC: Neuroprotective effects of huperzine A: new therapeutic targets for neurodegenerative disease. Trends Pharmacol. Sci. (2006) 27(12):619-625.
14. SAINT GEORGE-HYSLOP PH, PETIT A: Molecular biology and genetics of Alzheimer's disease. C R Biol. (2005) 328(2):119-130.
15. WEINER HL, FRENKEL D: Immunology and immunotherapy of Alzheimer's disease. Nat. Rev. Immunol. (2006) 6(5):404-416.
16. GUO T, HOBBS DW: Development of BACE1 inhibitors in Alzheimer's disease. Curr. Med. Chem. (2006) 13(15):1811-1129.
17. EVIN C, SERNEE MF, MASTERS CL: Inhibition of gamma-secretase as a therapeutic intervention for Alzheimer's disease: prospects, limitations and strategies. CNS Drugs (2006) 20(5):351-372.
18. AISEN PS: The development of anti-amyloid therapy for Alzheimer's disease: from secretase modulators to polymerisation inhibitors. CNS Drugs (2005) 19(12):989-996.
19. GASPARINI L, ONGINI E, WILCOCK D, MORGAN D: Activity of flurbiprofen and chemically related anti-inflammatory drugs in models of Alzheimer's disease. Brain Res. Brain Res. Rev. (2005) 48(2):400-408.
20. BARTUS RT, DEAN RL III, BEER B, LIPPA AS: The cholinergic hypothesis of geriatric memory dysfunction. Science (1982) 217(4558):408-417.
21. DBACHMAN DA, LEAVITT J: Human memory and the cholinergic system: a relationship to aging? Arch. Neurol. (1974) 30(2):113-121.
22. WHITEHOUSE PJ, PRICE DL, STRUBLE RG, CLARK AW, COYLE JT, DELON MR: Alzheimer's disease and senile dementia: loss of neurons in the basal forebrain. Science (1982) 215(4537):1237-1239.
23. NORDBERG A: Biological markers and the cholinergic hypothesis in Alzheimer's disease. Acta Neurol. Scand. Suppl. (1992) 139:54-58.
24. WILCOCK GK, ESIRI MM, BOWEN DM, SMITH CC: Alzheimer's disease: correlation of cortical choline acetyltransferase activity with the severity of dementia and histological abnormalities. J. Neurol. Sci. (1982) 57(2-3):407-417.
25. GIACOBINI E: Cholinesterase inhibitors: from the Calabar bean to Alzheimer therapy. In: Cholinesterases and Cholinesterase Inhibitors. E. Giacobini (Ed.), Martin Dunitz, London, UK (2000): 181-226.
26. SRAMEK JJ, CUTLER NR: RBC cholinesterase inhibition: a useful surrogate marker for cholinesterase inhibitor activity in Alzheimer's disease therapy? Alzheimer Dis. Assoc. Disord. (2000) 14(4):216-227.
27. BENCHERIF B, ENDRES CJ, MUSACHIO JL et al.: PET imaging of acctylcholinesterase using [11C]CP-126,998, a brain selective enzyme inhibitor. Synapse (2002) 45(1):1-9
28. KUHL DE, MINOSHIMA S, FREY KA, FOSTER NL, KILBOURN MR, KOEPPE RA: Limited donepezil inhibition of acetylcholinesterase measured with positron emission tomography in living Alzheimer cerebral cortex. Ann. Neurol. (2000) 48(3):391-395.
29. ROSEN WG, MOHS RC, DAVIS KL: A new rating scale for Alzheimer's disease. Am. J. Psychiatry (1984) 141(11):1356-1364.
30. CUMMINGS JL, MEGA M, GRAY K, ROSENBERG-THOMPSON S, CRUSI DA, GORBEIN J: The Neuropsychiatric Inventory: a comprehensive assessment of psychopathology in dementia. Neurology (1994) 44(12):2308-2314.
31. GALASKO D, BENNETT D, SANO M et al.: An inventory to assess activities of daily living for clinical trials in Alzheimer's disease. Alzheimer Dis. Assoc. Disord. (1997) 11(Suppl. 2):S33-S39.
32. GELINAS I, GAUTHIER L, MCINTYRE MC, GAUTHIER S: Development of a functional measure for person with Alzheimer's disease: the Disability Assessment for Dementia. Am. J. Occup. Ther. (1998) 53(5):472-481
33. KNOPMAN DS: Global change assessments in anti-Alzheimer clinical drug trials. Dement. Geriatr. Cogn. Disord. (1999) 9(Suppl. 3):8-15.
34. FOLSTEIN MF, FOLSTEIN SE, MCHUGH PR: 'Mini-mental state:' a practical method for grading the cognitive state of subjects for the clinician. J. Psychiatr. Res. (1975) 12(3):189-198.
35. ROGERS SL, FRIEDHOFF LT, DONEPEZIL STUDY GROUP: The efficacy and safety of donepezil in patients with Alzheimer's disease: results of a US multicentre, randomized, double-blind, placebo-controlled trial. The Donepezil Study Group. Dementia (1996) 7(6):293-303.
36. ROGERS SL, DOODY RS, MOHS RC et al.: Donepezil improves cognitive and global functioning in Alzheimer's disease: a 15-week, double-blind, placebo-controlled study. Arch. Int. Med. (1998) 158(9):1021-1031.
37. ROGERS SL, FARLOW MR, DOODY RS et al.: A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Neurology (1998) 50(1):136-145.
38. BURNS A, ROSSOR M, HECKER J et al.: The effects of donepezil in Alzheimer's disease - results from a multinational trial. Dement. Geriatr. Cogn. Disord. (1999) 10(3):237-244.
39. WINBLAD B, ENGEDAL D, SOINEN H et al.: Donepezil Nordic Study Group: a 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD. Neurology (2001) 57(3):489-495.
40. DOODY RS, GELDMACHER DS, GORDON B, PERDOMO CA, PRATT RD, FOR THE DONEPEZIL STUDY GROUP: Open-label multicenter Phase III extension of the safety and efficacy of donepezil in patients with Alzheimer's disease. Arch. Neurol. (2001) 58(3):427-433.
41. WINBLAD B, WIMO A, ENGEDAL K et al.: 3-year study of donepezil therapy in Alzheimer's disease: effects of early and continuous therapy. Dementia Geriatr. Cogn. Disord. (2006) 21:353-363.
42. DOODY RS, DUNN JK, CLARK CM et al.: Chronic donepezil treatment is associated with slowed cognitive decline in Alzheimer's disease. Dement. Geriatr. Cogn. Disord. (2001) 12:295-300.
43. WINBLAD B, ENGEDAL K, SOININEN H, WALDEMAR G, VERHEY E, WIMO A: Long-term efficacy of donepezil in patients with mild to moderate Alzheimer's disease: results from a 1-year placebo-controlled study and two-year follow up study. Int. Psychogeriatr. (2003) 15(Suppl. 2):293-294.
44. CUMMINGS JL: Challenges to demonstrating disease-modifying effects in Alzheimer's disease clinical trials. Alzheimer's & Dementia (2006) 2(4):263-271.
45. MANI RB: The evaluation of disease modifying therapies in Azlheimer's disease: a regulatory viewpoint. Stat. Med. (2004) 2:305-314.
46. SABBAGH MS, FARLOW MR, RELKIN N et al.: Do cholinergic therapies have a disease-modifying effects in Alzheimer's disease. Alzheimer's & Dementia (2006) 2:118-125.
47. SAMPAIO C: Alzheimer's disease: disease modifying trials. Where are we? Where do we need to go? A reflective paper. J. Nutr. Health Aging (2006) 10:113-115.
48. DAVIS KL, MOHS RC, MARIN D et al.: Cholinergic markers in elderly patients with early signs of Alzheimer's disease. JAMA (1999) 21(15):1401-1406.
49. DEKOSKY ST, IKONOMOVIC MD, STYREN SD et al.: Upregulation of choline acetyltransferase activity in hippocampus and frontal cortex of elderly subjects with mild cognitive impairment. Ann. Neurol. (2002) 51(2):145-155.
50. MUFSON EJ, MA SY, DILLIS J et al.: Loss of basal forebrain P75(NTR) immunoreactivity in subjects with mild cognitive impairment and Alzheimer's disease. J. Comp. Neurol. (2002) 443(2):136-153.
51. RIEPE MW: Cholinergic treatment: what are the early neuropathological targets? Eur. J. Neurol. (2005) 12(Suppl. 3):3-9.
52. PETERSEN RC, THOMAS RG, GRUNDMAN M et al.: Vitamin E and donepezil for the treatment of mild cognitive impairment. New Engl. J. Med. (2005) 352(23):2379-2388.
53. NORDBERG A: Emerging biology of the cholinergic system across the spectrum of Alzheimer's disease. Int. Psychogeriatr. (2006) 18(Suppl. 1):S3-S16.
54. KIMURA M, AKASOFU S, OGURA H, SAWADA K: Protective effect of donepezil against Aβ(1-40) neurotoxicity in rat septal neurons. Brain Res. (2005) 1047(1):72-84.
55. REID RT, SABBAGH MS: Effects of donepezil treatment on rat nicotinic receptor levels in vivo and in vitro. J. Alzheimer's Res. (2003) 5(6):429-436.
56. SHIMOHAMA S, KITARA T: Nicotinic receptor-mediated protection against β-amyloid neurotoxicity. Biol. Psychiatry (2001) 49(3):233-239
57. TAKADA-TAKATORI Y, KUME T, SUGIMOTO S, KATSUKI H, SUGIMOTO H, AKAIKE A: Acetylcholinesterase inhibitors used in treatment of Aizheimer's disease prevent glutamate neurotoxicity via nicotinic acetylcholine receptors and phosphatidylinositol 3-kinase cascade. Neuropharmacology (2006) 51(3):474-486.
58. FOX NC, COUSENS S, SCAHILL R et al.: Using serial registered brain magnetic resonance imaging to measure disease progression in Alzheimer's disease. Arch. Neurol. (2000) 57:339-344.
59. SHINOTOH H, FUKUSHI K, NAGATSUKA S, IRIE T: Acetylcholinesterase imaging: its use in therapy evaluation and design. Curr. Pharm. Des. (2004) 10(13):1505-1517.
60. KLUNK WE, ENGLER H, NORDBERG A et al.: Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann. Neurol. (2004) 55:306-319.
61. ALEXANDER GE, CHEN K, PIETRINI P, RAPOPORT SI, REIMAN EM: Longitudinal PET evaluation of cerebral metabolic decline in dementia: a potential outcome measure in Alzheimer's disease treatment studies. Am. J. Psychiatry (2002) 159:738-745.
62. LIN A, ROSS JR, HARRIS K et al.: Efficacy of proton magnetic resonance spectroscopy in neurological diagnosis and neurotherapeutic decision making. NeuroRx (2005) 2:197-214.
63. SUNDERLAND T, LINKER G, MIRZA N et al.: Decreased β-amyloid 1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer's disease. JAMA (2003) 289:2094-2103.
64. MAYEUX R, HONIG LS, TANG M-X et al.: Plasma Aβ40 and Aβ42 and Alzheimer's disease: relation to age, mortality, and risk. Neurology (2003) 61:1185-1190
65. SALA G, GALIMBERTI G, CANEVARI C et al.: Peripheral cytokine release in Alzheimer patients: correlation with disease severity. Neurobiol. Aging (2003) 24:909-914
66. PRATICÓ D, CLARK CM, LEE VM-Y et al.: Increased 8,12-iso-iPF2α-VI in Alzheimer's disease: correlatin of a noninvasive index of lipid peroxidation with disease severity. Ann. Neurol. (2000) 48:809-812.
67. KRISHNAN KR, CHARLES HC, DORAISWAMY PM et al.: Randomized, placebo-controlled trial of the effects of donepezil on neuronal markers and hippocampal vaolumes in Alzheimer's disease. Am. J. Psychiatry (2003) 160:2003-2011
68. TUNE L, TISEO PJ, IENI J et al.: Donepezil HCl (E2020) maintains functional brain activity in patients with Alzheimer's disease: results of a 24-week, double-blind, placebo-controlled study. Am. J. Geriatr. Psychiatry (2003) 11(2):169-177
69. JESSEN F, TRABER F, FREYMANN K, MAIER W, SCHILD HH, BLOCK W: Treatment monitoring and response prediction with MR spectroscopy in AD. Neurology (2006) 67(3):528-530.
70. USHUIJIMA Y, OKUYAMA C, MORI S, KUBOTA T, NAKAI T, NISHIMURA T: Regional cerebral blood flow in Alzheimer's disease: comparison between short and long-term donepezil therapy. Ann. Nucl. Med. (2006) 20(6):425-429.
71. STAFF RT, GEMMELL HG, SHANKS MF, MURRAY AD, VENNERI A: Changes in the rCBF images of patients with Alzheimer's disease receiving donepezil therapy. Nucl. Med. Commun. (2000) 21:37-41.
72. DARREH-SHORI T, MEURLING L, PETERSSON T et al.: Changes in the activity and protein levels of CSF acetylcholinesterases in relation to cognitive function of patients with mild Alzheimer's disease following chronic donepezil treatment. J. Neural Transm. (2006) 113(11):1791-1801.
73. ROGERS SL, FRIEDHOFF LT: Pharmacokinetic and pharmacodynamic profile of donepezil HCl following single oral doses. Br. J. Clin. Pharmacol. (1998) 46(Suppl. 1):1-6.
74. ROGERS SL, COOPER NM, SUKOVATY R, PEDERSEN JE, LEE JN, FRIEDHOFF LT: Pharmacokinetic and pharmacodynamic profile of doenepezil HCl following multiple oral doses. Br. J. Clin. Pharmacol. (1998) 46(Suppl. 1):7-12
75. TISEO PJ, ROGERS SL, FRIEDHOFF LT: Pharmacokinetic and pharmacodynamic profile of donepezil HCl following evening administration. Br. J. Clin. Pharmacol. (1998) 46(Suppl. 1):19-24.
76. TISEO PJ, PERDOMO CA, FRIEDHOFF LT: Metabolism and elimination of 14C-donepezil in healthy volunteers: a single-dose study. Br. J. Clin. Pharmacol. (1998) 46(Suppl. 1): 19-24.
77. EISAI, INC: Aricept® (donepezil hydrochloride) Package Insert.
78. ONISHI A, MIHARA M, KAMAKURA H et al.: Comparison of the pharmacokinetics of E2020, a new compound for Alzheimer's disease in healthy young and elderly subjects. Int. J. Clin. Pharmacol. Ther. Toxicol. (1993) 31(5):223-229.
79. HEYWOOD WM, MUKAETOVA-LADINSKA EB: Sex influence on cholinesterase inhibitor treatment in elderly individuals wih Alzheimer's disease. Am. J. Geriatr. Pharmacother. (2006) 4(3):273-286
80. GRIFFITH P, LICHTENBERG P, GOLDMAN R, PAYNE-PARRISH J: Safety and efficacy of donepezil in African-Americans with mild-to-moderate Alzheimer's disease. J. Natl. Med. Assoc. (2006) 98(10):1590-1597.
81. REYES JF, VARGAS R, KUMAR D, CULLEN EI, PERDOMO CA, PRATT RD: Steady-state pharmacokinetics, pharmacodynamics and tolerability of donepezil hydrochloride in hepatically impaired patients. Br. J. Clin. Pharmacol. (2004) 58(Suppl. 1):9-17.
82. NAGY CF. KUMAR D, CULLEN EI et al.: Steady-state pharmacokinetics and safety of donepezil HCl in subjects with moderately impaired renal function. Br. J. Clin. Pharmacol. (2004) 58(Suppl. 1):18-24.
83. SELTZER B, ZOLNOUNI P, NUNEZ M et al.: Efficacy of donepezil in early-stage Alzheimer's disease: a randomized placebo-controlled trial. Arch. Neurol. (2004) 61(12):1852-1856.
84. SCHMITT FA, CRAGAR D, ASHFORD JW et al.: Measuring cognition in advanced Alzheimer's disease for clinical trials. J. Neural Transm. Suppl. (2002) 62:135-148
85. FELDMAN H, GAUTHIER S, HECKER J et al.: A 24 week-, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease. Neurology (2001) 57(4):613-620.
86. TARIOT PN, CUMMINGS JL, KATZ IR et al.: A randomized, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting. J. Am. Geriatr. Soc. (2001) 49(12):1590-1599.
87. FELDMAN H, GAUTHIER S, HECKER J et al.: Efficacy and safety of donepezil in patients with more severe Alzheimer's disease: a subgroup analysis from a randomized, placebo-controlled trial. Int. J. Geriatr Psychiatry (2005) 20(6):559-569.
88. WINBLAD B, KILANDER L, ERIKSSON S et al.: Donepezil in patients with severe Alzheimer's disease: double-blind, parallel-group, placebo-controlled study. Lancet (2006) 367(9516):1057-1065.
89. EISAI Co Ltd: Donepezil. Press release, 14 October 2006.
90. SELTZER B: Cholinesterase inhibitors in the clinical management of Alzheimer's disease: importance of early and persistent treatment. J. International Med. Res. (2006) 34:339-347.
91. NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE (UK): Technology appraisal guidance 111. Donepezil, galantamine, rivastigmine (review) and memantine for the treatment of Alzheimer's disease. November 2006
92. PETERSEN RC, SMITH GE, WARING SC, IVNIK RJ, TANGALOS EG, KOKMEN E: Mild cognitive impairment: clinical characterization and outcome. Arch. Neurol. (1999) 56(3):303-308.
93. GAUTHIER S, REISBERG B, ZAUDIG M et al.: Mild cognitive impairment. Lancet (2006) 367(9518):1262-1270.
94. SALLOWAY S, FERRIS S, KLUGER A et al.: Efficacy of donepezil in mild cognitive impairment: a randomized, placebo-controlled trial. Neurology (2004) 63(4):651-657.
95. SAUNDERS AM, HULETTE O, WELSH-BOHMER KA et al.: Specificity, sensitivity, and predictive value of apolipoprotein E genotyping for sporadic Alzheimer's disease. Lancet (1996) 348(9020):90-93.
96. BIRKS J, FLICKER L: Donepezil for mild cognitive impairment. Cochrane Database Syst. Rev. (2006) 19(3):CD006104
97. SALLOWAY S: Buying time: management of mild cognitive impairment and early dementia. Int. Psychogeriatr. (2006) 18(Suppl. 1):S17-S23.
98. TOMLINSON BE, BLESSED G, ROTH M: Observations on the brains of demented old people. J. Neurol. Scis. (1970) 11(3):205-242.
99. ROMAN GC, TATEMICHI TH, ERKINJUNTTI T et al.: Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology (1993) 43(2):250-260.
100. BALLARD CG, BURTON EJ, BARBER R et al.: NINDS AIREN neuroimaging criteria do not distinguish stroke patients with and without dementia. Neurology (2004) 63:983-988.
101. KUMAR V, ANAND R, MESSINA J, HARTMAN R, VEACH J. An efficacy and safety analysis of Exelon in Alzheimer's disease patients with concurrent vascular disease. Eur. J. Neurol. (2000) 7(2):159-169.
102. BLACK S, ROMAN GC, GELDMACHER DS et al.: Efficacy and tolerability of donepezil in vascular dementia: positive results of a 24-week, multicenter, international, randomized, placebo-controlled clinical trial. Stroke (2003) 34(10):2323-2330.
103. WILKINSON D, DOODY R, HELME R et al.: Donepezil in vascular dementia: a randomized, placebo-controlled study. Neurology (2003) 61(4):479-486.
104. ROMAN GC, WILKINSON DG, DOODY RS, BLACK SE, SALLOWAY SP, SCHINDLER R: Donepezil in vascular dementia: combined analysis two large-scale studies. Dement. Geriatr. Cogn. Disord. (2005) 20(6):338-344.
105. PASSMORE AP, BAYER AJ, STEINHAGEN-THIESSEN E: Cognitive, global, and functional benefits of donepezil in Alzheimer's disease and vascular dementia: results from large-scale clinical trials. J. Neurol. Sci. (2005) 229-230:141-146.
106. LOPEZ OL, KULLER LH, BECKER JT et al.: Classification of vascular dementia in the Cardiovascular Health Study Cognition Study. Neurology (2005) 64:1539-1547.
107. MAYEUX R, DENARO J, HEMENEGILDO N et al.: A population-based investigation of Parkinson's disease with and without dementia: relationship to age and gender. Arch. Neurol. (1992) 49(5):492-497.
108. MCKEITH IG: Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the Consortium on DLB International Workshop. J. Alzheimers Dis. (2006) 9(Suppl. 3):417-423.
109. TIRABOSCHI P, HANSEN LA, ALFORD M et al.: Early and widespread cholinergic losses differentiate dementia with Lewy bodies from Alzheimer's disease. Arch. Gen. Psychiatry (2002) 59(10):946-951.
110. EMRE M, AARSLAND D, ALBANESE A et al.: Rivastigmine for dementia associated with Parkinson's disease. N. Engl. J. Med. (2004) 351(24):2509-2518.
111. RAVINA B, PUTT M, SIDEROWF A et al.: Donepezil for dementia in Parkinson's disease: a randomized, double blind, placebo controlled, crossover study. J. Neurol. Neurosurg. Psychiatry (2005) 76(7):934-939.
112. TOUCHON J, BERGMAN H, BULLOCK R, RAPATZ C, NAGEL J, LANE R: Response to rivastigmine or donepezil in Alzheimer's patients with symptoms suggestive of concomitant Lewy body pathology. Curr. Med. Res. Opin. (2006) 22(1):49-59.
113. MIYASAKI JM, SHANNON K, VOOM V et al.: Practice parameter: evaluation and treatment of depression, psychosis, and dementia in Parkinson's disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology (2006) 66(7):996-1002.
114. MORI S, MORI E, ISEKI E, KOSAKA K: Efficacy and safety of donepezil in patients with dementia with Lewy bodies: preliminary findings from an open-label study. Psychiatry Clin. Neurosci. (2006) 60(2):190-195.
115. THOMAS AJ, BURN DJ. ROWAN EN et al.: A comparison of the efficacy of donepezil in Parkinson's disease and dementia with Lewy bodies. Int. J. Geriatr. Psychiatry (2005) 20(10):938-944.
116. BEVERSDORF DQ, WARNER JL, DAVIS RA, SHARMA UK, NAKARAJA HN, SCHARRE DW: Donepezil in the treatment of dementia with Lewy bodies. Am. J. Geriatr. Psychiatry (2004) 12(5):542-544
117. SHI J, SHAW CL, DuPLESSIS D et al.: Histopathological changes underlying frontotemporal lobar dementia with clinicopathological correlation. Acts Neuropath. (2005) 110(5):501-512.
118. DILAZZARO V, PILATO F, DILEONE M et al.: In vivo cholinergic circuit evaluation in frontotemporal and Alzheimer dementias. Neurology (2006) 66(7):1111-1113.
119. MORETTI R, TORRE P, ANTONELLO RM, CATTARUZZA T, CASSATO G, BAVA A: Rivastigmine in frontotemporal dementia: an open-label study. Drugs Aging (2004) 21(14):931-937.
120. MENDEZ MF, SHAPIRA JS, McMURTRAY A, LICHT E: Preliminary findings: behavioral worsening on donepezil in patients with frontotemporal dementia. Am. J. Geriatr. Psychiatry (2007) 15(1):84-87.
121. HESTON LL: Down's syndrome and Alzheimer's dementia: defining an association. Psychiatr. Dev. (1984) 2(4):287-294.
122. PRASHER VP, HUXLEY A, HAQUE MS, DOWN'S SYDROME AGEING STUDY GROUP: A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Down's syndrome and Alzheimer's disease - pilot study. Int. J. Geriatr Psychiatry (2002) 17(3):270-278.
123. KONDOH T, AMAMOTO N, DOI T et al.: Dramatic improvement in Down's syndrome-associated cognitive impairment with donepezil. Ann. Pharmacother. (2005) 39(3):563-566.
124. HELLER JH, SPIRIDIGLIOZZI GA, SULLIVAN JA, DORAISWAMY PM, KRISHNAN RR, KISHNANI PS: Donepezil for the treatment of language deficits in adults with Down's syndrome: a preliminary 24-week open trial. Am. J. Med. Genet. A (2003) 116(2):111-116.
125. JOHNSON N, FAHEY C, CHICOINE B, CHONG G, GITELMAN D: Effects of donepezil on cognitive functioning in Down's syndrome. Am. J. Ment. Retard. (2003) 108(6):367-372.
126. SELTZER B, SOMMER BR, KISHNANI PS: Safety, efficacy, and tolerability of donepezil in young adults with Down's syndrome. (2004) Program no. 665.15 Abstract viewer/itinerary planner, Washington DC, Society for Neuroscience.
127. KRUPP LB, CHRISTODOULOU C, MELVILLE P, SCHERL WF, MACALLISTER WS, ELKINS LE: Donepezil improved memory in multiple sclerosis in a randomized clinical trial. Neurology (2004) 63(9):1579-1585.
128. CHRISTODOULOU C, MELVILLE P, SCHERL WF, MACALLISTER WS, ELKINS LE, KRUPP LB: Effects of donepezil on memory and cognition in multiple sclerosis. J. Neurol. Sci. (2006) 245(1-2):127-136.
129. WILENS TE, BIEDERMAN J, WONG J, SPENCER TJ, PRINCE JB: Adjunctive donepezil in attention deficit hyperactivity disorder youth: case series. J. Child Adolesc. Psychopharmacol. (2000) 10(3):217-222.
130. DOYLE RL, FRAZIER J, SPENCER TJ, GELLER D, BIEDERMAN J, WILENS T: Donepezil in the treatment of ADHD-like symptoms in youths with pervasive developmental disorder: a case series. J. Atten. Disord. (2006) 9(3):543-549.
131. HARDAN AY, HANDEN BL: A retrospective open trial of adjunctive donepezil in children and adolescents with autistic disorder. J. Clin. Adolesc. Psychopharmacol. (2002) 12(3):237-241.
132. HOOPES SP: Donepezil for Tourette's disorder and ADHD. J. Clin. Psychopharmacol. (1999) 19(4):381-387.
133. ZHANG L, PLOTKIN RC, WANG G, SANDEL ME, LEE S: Cholinergic augmentation with donepezil enhances recovery in short-term memory and sustained attention after traumatic brain injury. Arch. Phys. Med. Rehabil. (2004) 85(7): 1050-1055.
134. TENOVUO O: Central acetylcholinesterase inhibitors in the treatment of chronic traumatic brain injury-clinical experience in 111 patients. Prog. Neuropsychopharmacol. Biol. Psychiatry (2005) 29(1):61-67.
135. BUCHANAN RW, SUMMERFELT A, TEK C, GOLD J: AN open-labeled trial of adjunctive donepezil for cognitive impairments in patients with schizophrenia. Schizophren. Res. (2003) 59(1):29-33.
136. ERICKSON SK, SCHWARZKOPF SB, PALUMBO D, BADGLEY-FLEEMAN J, SMIRNOW AM, LIGHT GA: Efficacy and tolerability of low-dose donepezil in schizophrenia. Clin. Neuropharmacol. (2005) 28(4):179-184.
137. LEE BJ, LEE JG, KIM YH: A 12-week, double-blind, placebo-controlled trial of donepezil as an adjunct to haloperidol for treating cognitive impairments in patients with chronic schizophrenia. J. Psychopharmacol. (2006) Nov 8 [Epub ahead of print].
138. ZARIT SH, REEVES KE, BACH-PETERSON J: Relatives of the impaired elderly: correlates of feelings of burden. The Gerontologist (1980) 20(6):649-655.
139. LINGLER JH, MARTIRE LM, SCHULZ R: Caregiver-specific outcomes in antidementia clinical drug trials: a systematic review and meta-analysis. J. Am. Geriatr. Soc. (2005) 53(6):983-990.
140. FELDMAN H, GAUTHIER S, HECKER J et al.: Efficacy of donepezil on maintenance of activities of daily living in patients with moderate to severe Alzheimer's disease and the effect on caregiver burden. J. Am. Geriatr. Soc. (2003) 51(6):737-744.
141. WIMO A, WINBLAD B, SHAH SN, CHIN W, ZHANG R, MCRAE T: Impact of donepezil treatment for Alzheimer's disease on caregiving time. Curr. Med. Res. Opin. (2004) 20(8):1221-1225.
142. FILLIT HM, GUTTERMAN EM, BROOKS RL: Impact of donepezil on caregiving burden for patients with Alzheimer's disease. Int. Psychogeriatr. (2000) 12(3):389-401.
143. COURTNEY C, FARRELL D, GRAY R et al.: Long term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomized, double-blind trial. Lancet (2004) 363:2105-2115.
144. BLACK SE, SZALAI: Are there long-term benefits of donepezil in Alzheimer's disease? CMAJ (2004) 171(10):1174-1175.
145. GELDMACHER DS, PROVENZANO G, MCRAE T et al.: Donepezil is associated with delayed nursing home placement in patients with Alzheimer's disease. J. Am. Geriatr. Soc. (2003) 51:937-944.
146. LOPEZ OL, BECKER JT, WISNIEWSKI S, SAXTON J, KAUFER DJ, DEKOSKY ST: Cholinesterase inhibitor treatment alters the natural history of Alzheimer's disease. J. Neurol. Neurosurg. Psychiatry (2002) 72:310-314.
147. FELDMAN H, GAUTHIER S, HECKER J et al.: Economic evaluation of donepezil in moderate to severe Alzheimer's disease. Neurology (2004) 63(4):644-650.
148. NEUMANN PJ, HERMANN RC, KUNTZ KM et al.: Cost-effectiveness of donepezil in the treatment of mild or moderate Alzheimer's disease. Neurology (1999) 52(6):1138-1145.
149. JONSSON L, LINDGREN P, WIMO A, JONSSON B, WINBLAD B: The cost-effectiveness of donepezil therapy in Swedish patients with Alzheimer's disease: a Markov model. Clin. Ther (1999) 21(7):1230-1240.
150. O'BRIEN BJ, GOEREE R, HUX M et al.: Economic evaluation of donepezil for the treatment of Alzheimer's disease in Canada. J. Am. Geriatr. Soc. (1999) 47(5):570-578.
151. STEWART A, PHILLIPS R, DEMPSEY G: Pharmacotherapy for people with Alzheimer's disease: a Markov-cycle evaluation of five years' therapy using donepezil. Int. J. Geriatr. Psychiatry (1998) 13(7):445-453.
152. LOVEMAN E, GREEN C, KIRBY J et al.: The clinical and cost-effectiveness of donepezil, rivastigmine, galantamine, and memantine for Alzheimer's disease. Health Technol. Assess. (2006) 10(1):iii-iv, ix-xi, 1-160.
153. GREEN C, PICOT J, LOVEMAN E, TAKEDA A, KIRBY J, CLEGG A: Modelling the cost effectiveness of cholinesterase inhibitors in the management of mild to moderately severe Alzheimer's disease. Pharmacoeconomics (2005) 23(12):1271-1282.
154. HAGER K, CALABRESE P, FROLICH L, GOBEL C, BERGER FM: An observational clinical study of the efficacy and tolerability of donepezil in the treatment of Alzheimer's disease. Dement. Geriatr. Cogn. Disord. (2003) 15(4):189-198.
155. RELKIN NR, REICHMAN WE, ORAZEM J, MCRAE T: A large, community-based, open-label trial of donepezil in the treatment of Alzheimer's disease. Dement. Geriatr. Cogn. Disord. (2003) 16(1):15-24
156. BOADA-RIVERA M, BRODATY H, CRAS P et al.: Efficacy and safety of donepezil in patients with Alzheimer's disease: results of a global, multinational, clinical experience study. Drugs Aging (2004) 21(1):42-53.
157. FROELICH L, GERTZ HJ, HEUN R et al.: Donepezil for Alzheimer's disease in clinical practice-The DONALD Study: a multicenter 24-week clinical trial in Germany. Dement. Geriatr. Cogn. Disord. (2004) 18(1):37-43.
158. ROCKWOOD K, BLACK SE, BEDARD MA, TRAN T, LUSSIER I: Specific symptomatic changes following donepezil treatment of Alzheimer's disease: a multi-centre, primary care, open-label study. Int. J. Geriatr. Psychiatry (2006) Sep 27 [Epub ahead of print].
159. JOHANSSEN P, SALMON E, HAMPEL H et al.: Assessing therapeutic efficacy in progressive disease: a study of donepezil in Alzheimer's disease. CNS Drugs (2006) 20(4):311-325.
160. KLINGER T, IBACH B, SCHOENKNECHT P et al.: Effect of donepezil in patients with Alzheimer's disease previously untreated or treated with memantine or nootropic agents in Germany: an observational study. Curr. Med. Res. Opin. (2005) 21(5):723-732.
161. BIZZARRO A, MARRA C, ACCIARRI A et al.: Apolipoprotein E 4̇ allele differentiates the clinical response to donepezil in Alzheimer's disease. Dement. Geriatr. Cogn. Disord. (2005) 20(4):254-261.
162. RIGAUD AS, TRAYKOV L, LATOUR F, COUDERC R, MOULIN F, FORETTE F: Presence or absence of at least one 4̇allele and gender are not predictive for the response to donepezil treatment in Alzheimer's disease. Pharmacogenetics (2002) 12(5):415-420.
163. BLESSA R, BULLOCK R, HE Y et al.: Effect of butyrylcholinesterase genotype on the response to rivastigmine or donepezil in younger patients with Alzheimer's disease. Pharmacogenet. Genomics (2006) 16(11):771-774.
164. FOLDI NS, WHITE RE, SCHAEFER LA: Detecting effects of donepezil on visual selective attention using signal detection parameters in Alzheimer's disease. Int. J. Geriatr. Psychiatry (2005) 20(5):485-488.
165. SAYKIN AJ, WISHART HA, RABIN LA et al.: Cholinergic enhancement of frontal lobe activity in mild cognitive impairment. Brain (2004) 127(7):1574-1583.
166. BOHNEN NI, KAUFER DI, HENDRICKSON R et al.: Degree of inhibition of cortical acetylcholinesterase activity and cognitive effects by donepezil treatment in Alzheimer's disease. J. Neurol. Neurosurg. Psychiatry (2005) 76(3):315-319.
167. KAASINEN V, NAGREN K, JARVENPAA T et al.: Regional effects of donepezil and rivastigmine on cortical acetylcholinesterase activity in Alzheimer's disease. J. Clin. Psychopharmacol. (2002) 22(6):615-620.
168. JACKSON S, HAM RJ, WILKINSON D: The safety and tolerability of donepezil in patients with Alzheimer's disease. Br. J. Clin. Pharmacol. (2004) 58(suppl 1):1-8.
169. SCHNEIDER LS: Cholinesterase inhibitors and risk of death in vascular dementia. Presented at the 10th International Conference on Alzheimer's disease and Related Disorders. Madrid, Spain (19 July 2006).
170. BURNS A, O'BRIEN J: Clinical practice with anti-dementia drugs: a consensus statement from British Association for Psychopharmacology. J. Psychopharmacol. (2006) 20(6):732-755.
171. CALTAGIRONE C, BIANCHETTI A, DILUCA M et al.: Guidelines for the treatment of Alzheimer's disease from the Italian Association of Psychogeriatrics. Drugs Aging (2005) 22(Suppl. 1):1-26.
172. ROBINSON DH, PLOSKER GL: Galantamine extended release. CNS Drugs (2006) 20(8):673-681.
173. WINBLAD B, CUMMINGS J et al.: IDEAL: a 24 week placebo controlled study of the first transdermal patch in Alzheimer's disease: rivastgmine patch versus capsule.